TYK-2-INHIBITOR

European patent · EP4168398 · In force

Register entry

Publication number
EP4168398
Application number
EP21829711
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jun 21, 2021
Published
Apr 26, 2023
Granted
Jun 3, 2026
Protection ends at the latest
Jun 20, 2041
Next annual fee due
Jun 30, 2026
IPC classes
C07D 401/14 (2006.01)
C07D 403/14 (2006.01)
A61K 31/444 (2006.01)
A61K 31/44 (2006.01)
A61P 29/00 (2006.01)
A61P 37/00 (2006.01)
C07D 401/04 (2006.01)
C07D 213/75 (2006.01)
C07D 405/14 (2006.01)
C07D 409/14 (2006.01)
C07D 413/14 (2006.01)
C07D 417/14 (2006.01)
C07D 487/04 (2006.01)
C07D 491/147 (2006.01)
C07D 493/04 (2006.01)
C07D 495/04 (2006.01)
C07D 497/04 (2006.01)
C07D 498/04 (2006.01)
C07D 498/10 (2006.01)
C07D 513/14 (2006.01)
Priority
WO PCT/CN2020/097557 22.06.2020
WO PCT/CN2020/119750 30.09.2020
WO PCT/CN2021/093815 14.05.2021
PCT application
PCT/CN2021/101282 21.06.2021
PCT publication
WO2021/259208 30.12.2021
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jun 3, 2026

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 03.06.2026

Parties

Holder

BeOne Medicines I GmbH

Aeschengraben 27, 4051 Basel

Inventor

GUO, Yunhang

Beijing 102206, CN

WANG, Zhiwei

Beijing 102206, CN

WANG, Qiuwen

Beijing 102206, CN

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.